Albendazole, primarily an anthelmintic agent, has been investigated for potential off-label use in Depersonalization-derealization disorder (DPDR) due to its proposed immunomodulatory and anti-inflammatory properties. Its mechanism may involve reducing neuroinflammation and modulating neurological processes that contribute to the dissociative symptoms of DPDR, though more research is needed to establish definitive efficacy and standard treatment protocols.